Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults
